ReviewMarine drugs2023
Cyanobacteria: A Promising Source of Antifungal Metabolites.
Review in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Next-Generation Cyanobacterial Biocontrol Agents for Crop Fungal Diseases: Molecular Mechanisms, Omics Insights, Applications, and Biosafety Considerations.Journal of basic microbiology · 2026Review
- Structure, Biosynthesis, and Bioactivity of Nostolysamides.Biochemistry · 2026Article
- Structure, biosynthesis, and bioactivity of nostolysamides.bioRxiv : the preprint server for biology · 2026Article
- Antimicrobial and Cytotoxic Activities of Biogenic Nanoparticles Produced by Cyanobacteria.Chembiochem : a European journal of chemical biology · 2026Review
- Green-synthesized Desertifilum silver nanoparticles induce BAX/BCL-2 mediated apoptosis in Ehrlich carcinoma.BMC biotechnology · 2026Article
- Green genes from blue greens: challenges and solutions to unlocking the potential of cyanobacteria in drug discovery.Natural product reports · 2026Review
- Sustainable approaches to manage fusarium root rot in faba bean.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Algae and Cyanobacteria Fatty Acids and Bioactive Metabolites: Natural Antifungal Alternative AgainstMicroorganisms · 2025Review
- The Chemistry of Phytoplankton.Chemical reviews · 2024Review
- Marine Cyanobacteria: A Rich Source of Structurally Unique Anti-Infectives for Drug Development.Molecules (Basel, Switzerland) · 2024Review
- Cyanobacteria-Fungi Co-Cultures: Which Partner Contributes to Antifungal Activity?Current microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cyanobacteria are a rich source of secondary metabolites, and they have received a great deal of attention due to their applicability in different industrial sectors. Some of these substances are known for their notorious ability to inhibit fungal growth. Such metabolites are very chemically and biologically diverse. They can belong to different chemical classes, including peptides, fatty acids, alkaloids, polyketides, and macrolides. Moreover, they can also target different cell components. Filamentous cyanobacteria have been the main source of these compounds. This review aims to identify the key features of these antifungal agents, as well as the sources from which they are obtained, their major targets, and the environmental factors involved when they are being produced. For the preparation of this work, a total of 642 documents dating from 1980 to 2022 were consulted, including patents, original research, review articles, and theses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.